Queensland bioresearchers have discovered a promising method for treating a common bacterial infection afflicting cystic fibrosis patients.
The Australian branch of agricultural biotechnology giant Monsanto today refuted reports that its herbicide resistant genetically modified wheat seed was taking longer than expected to gain approval in the US.
Queensland molecular farming start-up Farmacule Bioindustries has scored a mini-coup by appointing ex-Dow Chemical heavyweight Dr Paul Zorner to its board.
The Australian Shareholders Association (ASA) has clashed with Sydney biotech company Peptech over the company's remuneration of non-executive board members.
Pig hearts, kidneys and livers could be available for transplant into humans within five to seven years, according to the latest reports from the American Association for the Advancement of Science meeting currently underway in Boston.
Two major multinational pharmaceutical companies and two ASX-listed biotechs are vying for the a new biopharmaceutical platform technology developed by Acyte Biotech, a spin-off company from the University of New South Wales.
Analysts and industry experts are widely predicting biotechnology and life sciences to be strong growth areas this year, but in comparison to other Asian markets, Hong Kong seems off the pace.
Blood products and vaccine manufacturer CSL has announced it more than doubled its interim profit to $57.5 million on the back of its acquisition of Swiss plasma supplier ZLB last year.
Cochlear shares gained $A3.90 (+10.1 per cent) to close at $A42.50 on February 18 after half-yearly reports for the six months ended 31 December 2001 showed that the company would meet its long-term growth target of 20 per cent a year.
Sydney-based nanotechnology company Ambri Limited is on track to deliver its first biosensor to the Australian market in June, after hooking up with local instrument manufacturer Vision Biosystems.
Blue carnations won't be appearing in Tasmanian gardens, after a Melbourne molecular breeder vowed it "would not waste its time" trying to have a GMO ban in the state overturned.
A promising development pipeline is keeping spirits high at Amrad Corporation despite its posting a $54.6 million drop in revenues in the last half of 2001.
Voluntary bans by local farmers are a preferable way of creating GM crop-free areas than passing State laws, says Queensland Premier Peter Beattie.
The Melbourne company behind a tanning drug has posted a $1.5 million interim loss as it pushes towards advanced human trials.
IBM and software developer Accelrys have announced an alliance aimed at developing collaborative applications that will help pharmaceutical companies shorten the development cycles for new drugs.